Talazoparib

Manufactured by Pfizer

Talazoparib is a lab equipment product developed by Pfizer. It is a poly(ADP-ribose) polymerase (PARP) inhibitor used in research applications. Talazoparib functions by inhibiting the activity of PARP enzymes, which are involved in DNA repair processes.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Histone h3, by Santa Cruz Biotechnology (1 mentions) α tubulin, by Santa Cruz Biotechnology (1 mentions) Necrostatin 1, by Selleck Chemicals (1 mentions) Dimethyl sulfoxide (dmso), by Thermo Fisher Scientific (1 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Polybrene, by Merck Group (1 mentions) Puromycin, by Merck Group (1 mentions) Sodium orthovanadate, by Merck Group (1 mentions) Mcl 1, by Santa Cruz Biotechnology (1 mentions) γh2ax, by Santa Cruz Biotechnology (1 mentions) Neurod1, by Santa Cruz Biotechnology (1 mentions) Parp1, by Cell Signaling Technology (1 mentions) Z vad fmk, by Selleck Chemicals (1 mentions) Caspase 3, by Santa Cruz Biotechnology (1 mentions) Mg132, by Selleck Chemicals (1 mentions)

2 protocols using talazoparib

Comprehensive Biochemical Profiling of Cell Death

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against the following proteins were used: Cell Signaling Technology: PARP1 (#9542), γH2AX (#9718), Caspase 3 (#9665), α-tubulin (#3873), Histone H3 (#4499), NEUROD1 (#4373), Myc (#2276), hemagglutinin (#3724), HUWE1 (#5695), and MCL-1 (#94296); Santa Cruz Biotechnology: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#sc-32233), ASCL1 (#sc-374550), POU2F3 (#sc-293402), PCNA (#sc-56), Myc (#sc-40), and ubiquitin (#sc-8017); Trevin: PAR (#4335-MC-100); MilliporeSigma: Flag (#F7425); and ActiveMotif: PARP2 (#39743). The following reagents were used (1 μM for 48 hours, if not indicated): Talazoparib (Pfizer Inc.), MG132 (10 μM), and Z-VAD-FMK (Z-VAD, 50 μM) were all purchased from Selleck; Necrostatin-1 (20 μM), Ferrostatin-1 (10 μM), Ac-FLTD-CMK (10 μM), DMSO, and Lipofectamine 2000 were all purchased from Thermo Fisher Scientific; JQ-1 was purchased from AddoQ Bioscience; chloroquine diphosphate salt (chloroquine; 50 μM), CHX (10 μg/ml), polybrene (8 μg/ml), puromycin (2 μg/ml), NEM (25 mM), sodium orthovanadate (2 mM), and sodium fluoride (20 mM) were purchased from MilliporeSigma. See also table S7.

Kim C., Wang X.D., Liu Z., Hao J., Wang S., Li P., Zi Z., Ding Q., Jang S., Kim J., Luo Y., Huffman K.E., Pal Choudhuri S., del Rio S., Cai L., Liang H., Drapkin B.J., Minna J.D, & Yu Y. (2024). Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science Advances, 10(3), eadh2579.

+ Open protocol

+ Expand

Decitabine and Talazoparib Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Decitabine was administered IV daily for 5 days every 28 days, and for
10 days in the last cohort. Talazoparib was initiated orally daily for 28 days
on Day 1 of Cycle 1. On days when both decitabine and Talazoparib were given,
decitabine was given after Talazoparib to ensure simultaneous exposure to both
drugs. Talazoparib was administered regardless of food intake.
Treatment continued on an ongoing basis until disease progression,
intercurrent illness preventing further treatment, unacceptable adverse event(s)
or patient or physician decision to stop.
Talazoparib was provided by Pfizer Inc. (New York, NY).

Baer M.R., Kogan A.A., Bentzen S.M., Mi T., Lapidus R.G., Duong V.H., Emadi A., Niyongere S., O’Connell C.L., Youngblood B.A., Baylin S.B, & Rassool F.V. (2022). Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(7), 1313-1322.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!